Cargando…

Decline in Antimicrobial Consumption and Stagnation in Reducing Disease Burden due to Antimicrobial Resistance in Japan

INTRODUCTION: Antimicrobial resistance (AMR) is a major global health threat. While antimicrobial consumption (AMC) in Japan substantially decreased after implementation of the AMR National Action Plan, the disease burden due to AMR seems to be unchanged. The main objective of this study is to exami...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuzuki, Shinya, Koizumi, Ryuji, Matsunaga, Nobuaki, Ohmagari, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390429/
https://www.ncbi.nlm.nih.gov/pubmed/37318709
http://dx.doi.org/10.1007/s40121-023-00829-7
_version_ 1785082473840902144
author Tsuzuki, Shinya
Koizumi, Ryuji
Matsunaga, Nobuaki
Ohmagari, Norio
author_facet Tsuzuki, Shinya
Koizumi, Ryuji
Matsunaga, Nobuaki
Ohmagari, Norio
author_sort Tsuzuki, Shinya
collection PubMed
description INTRODUCTION: Antimicrobial resistance (AMR) is a major global health threat. While antimicrobial consumption (AMC) in Japan substantially decreased after implementation of the AMR National Action Plan, the disease burden due to AMR seems to be unchanged. The main objective of this study is to examine the relationship between AMC and the disease burden due to AMR in Japan. METHODS: We estimated the annual population-standardized AMC from 2015 to 2021 using defined daily doses (DDDs) per 1000 inhabitants per day (DIDs) and the disease burden due to bloodstream infections caused by nine major antimicrobial-resistant bacteria (AMR-BSIs) from 2015 to 2021 using disability-adjusted life years (DALYs). We then examined the correlation between AMC and DALYs using Spearman’s rank correlation coefficient and cross-correlation function. Spearman’s [Formula: see text] > 0.7 was considered to indicate a strong correlation. RESULTS: The sales amounts of third-generation cephalosporins, fluoroquinolones, and macrolides were 3.82 DIDs, 2.71 DIDs, and 4.59 DIDs, respectively, in 2015, but 2.11, 1.48, and 2.72 in 2021. This corresponded to reductions of 44.8%, 45.4%, and 40.7% during the study period. DALYs due to AMR-BSIs were 164.7 per 100,000 population in 2015 but 195.2 per 100,000 in 2021. Spearman’s rank correlation coefficients between AMC and DALYs were − 0.37 (total antibiotics), − 0.50 (oral antibiotics), − 0.43 (third-generation cephalosporins), − 0.5 (fluoroquin,olones) and − 0.5 (macrolides). No obvious cross-correlations were found. CONCLUSIONS: Our results reveal that changes in AMC are not associated with DALYs caused by AMR-BSIs. AMR countermeasures besides efforts to reduce inappropriate AMC might be necessary to mitigate the disease burden due to AMR. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-023-00829-7.
format Online
Article
Text
id pubmed-10390429
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-103904292023-08-02 Decline in Antimicrobial Consumption and Stagnation in Reducing Disease Burden due to Antimicrobial Resistance in Japan Tsuzuki, Shinya Koizumi, Ryuji Matsunaga, Nobuaki Ohmagari, Norio Infect Dis Ther Original Research INTRODUCTION: Antimicrobial resistance (AMR) is a major global health threat. While antimicrobial consumption (AMC) in Japan substantially decreased after implementation of the AMR National Action Plan, the disease burden due to AMR seems to be unchanged. The main objective of this study is to examine the relationship between AMC and the disease burden due to AMR in Japan. METHODS: We estimated the annual population-standardized AMC from 2015 to 2021 using defined daily doses (DDDs) per 1000 inhabitants per day (DIDs) and the disease burden due to bloodstream infections caused by nine major antimicrobial-resistant bacteria (AMR-BSIs) from 2015 to 2021 using disability-adjusted life years (DALYs). We then examined the correlation between AMC and DALYs using Spearman’s rank correlation coefficient and cross-correlation function. Spearman’s [Formula: see text] > 0.7 was considered to indicate a strong correlation. RESULTS: The sales amounts of third-generation cephalosporins, fluoroquinolones, and macrolides were 3.82 DIDs, 2.71 DIDs, and 4.59 DIDs, respectively, in 2015, but 2.11, 1.48, and 2.72 in 2021. This corresponded to reductions of 44.8%, 45.4%, and 40.7% during the study period. DALYs due to AMR-BSIs were 164.7 per 100,000 population in 2015 but 195.2 per 100,000 in 2021. Spearman’s rank correlation coefficients between AMC and DALYs were − 0.37 (total antibiotics), − 0.50 (oral antibiotics), − 0.43 (third-generation cephalosporins), − 0.5 (fluoroquin,olones) and − 0.5 (macrolides). No obvious cross-correlations were found. CONCLUSIONS: Our results reveal that changes in AMC are not associated with DALYs caused by AMR-BSIs. AMR countermeasures besides efforts to reduce inappropriate AMC might be necessary to mitigate the disease burden due to AMR. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40121-023-00829-7. Springer Healthcare 2023-06-15 2023-07 /pmc/articles/PMC10390429/ /pubmed/37318709 http://dx.doi.org/10.1007/s40121-023-00829-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Tsuzuki, Shinya
Koizumi, Ryuji
Matsunaga, Nobuaki
Ohmagari, Norio
Decline in Antimicrobial Consumption and Stagnation in Reducing Disease Burden due to Antimicrobial Resistance in Japan
title Decline in Antimicrobial Consumption and Stagnation in Reducing Disease Burden due to Antimicrobial Resistance in Japan
title_full Decline in Antimicrobial Consumption and Stagnation in Reducing Disease Burden due to Antimicrobial Resistance in Japan
title_fullStr Decline in Antimicrobial Consumption and Stagnation in Reducing Disease Burden due to Antimicrobial Resistance in Japan
title_full_unstemmed Decline in Antimicrobial Consumption and Stagnation in Reducing Disease Burden due to Antimicrobial Resistance in Japan
title_short Decline in Antimicrobial Consumption and Stagnation in Reducing Disease Burden due to Antimicrobial Resistance in Japan
title_sort decline in antimicrobial consumption and stagnation in reducing disease burden due to antimicrobial resistance in japan
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390429/
https://www.ncbi.nlm.nih.gov/pubmed/37318709
http://dx.doi.org/10.1007/s40121-023-00829-7
work_keys_str_mv AT tsuzukishinya declineinantimicrobialconsumptionandstagnationinreducingdiseaseburdenduetoantimicrobialresistanceinjapan
AT koizumiryuji declineinantimicrobialconsumptionandstagnationinreducingdiseaseburdenduetoantimicrobialresistanceinjapan
AT matsunaganobuaki declineinantimicrobialconsumptionandstagnationinreducingdiseaseburdenduetoantimicrobialresistanceinjapan
AT ohmagarinorio declineinantimicrobialconsumptionandstagnationinreducingdiseaseburdenduetoantimicrobialresistanceinjapan